Arvinas is a clinical-stage biotechnology company. Co.'s investigational clinical stage programs include: ARV-471, which is an investigational orally bioavailable PROTAC protein degrader designed for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; bavdegalutamide (ARV-110), which is an investigational orally bioavailable PROTAC protein degrader designed for the treatment of men with metastatic castration-resistant prostate cancer, or mCRPC; and ARV-766, which is an investigational orally bioavailable PROTAC protein degrader designed to target AR with a different profile than bavdegalutamide, as a potential treatment for men with mCRPC. The ARVN average annual return since 2018 is shown above.
The Average Annual Return on the ARVN average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ARVN average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ARVN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|